Handelsbanken Fonder’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.16M | Hold |
23,900
| – | – | ﹤0.01% | 895 |
|
|
2025
Q1 | $813K | Sell |
23,900
-500
| -2% | -$17K | ﹤0.01% | 1022 |
|
|
2024
Q4 | $960K | Sell |
24,400
-4,700
| -16% | -$185K | ﹤0.01% | 983 |
|
|
2024
Q3 | $1.37M | Sell |
29,100
-71,200
| -71% | -$3.34M | 0.01% | 812 |
|
|
2024
Q2 | $5.42M | Buy |
100,300
+83,600
| +501% | +$4.52M | 0.02% | 411 |
|
|
2024
Q1 | $1.14M | Buy |
16,700
+1,000
| +6% | +$68.1K | ﹤0.01% | 794 |
|
|
2023
Q4 | $983K | Buy |
15,700
+1,700
| +12% | +$106K | ﹤0.01% | 807 |
|
|
2023
Q3 | $635K | Hold |
14,000
| – | – | ﹤0.01% | 939 |
|
|
2023
Q2 | $786K | Buy |
14,000
+1,500
| +12% | +$84.2K | ﹤0.01% | 840 |
|
|
2023
Q1 | $565K | Hold |
12,500
| – | – | ﹤0.01% | 950 |
|
|
2022
Q4 | $508K | Buy |
12,500
+2,700
| +28% | +$110K | ﹤0.01% | 950 |
|
|
2022
Q3 | $640K | Hold |
9,800
| – | – | ﹤0.01% | 832 |
|
|
2022
Q2 | $596K | Sell |
9,800
-300
| -3% | -$18.2K | ﹤0.01% | 924 |
|
|
2022
Q1 | $634K | Hold |
10,100
| – | – | ﹤0.01% | 1034 |
|
|
2021
Q4 | $765K | Hold |
10,100
| – | – | ﹤0.01% | 1054 |
|
|
2021
Q3 | $1.13M | Sell |
10,100
-100
| -1% | -$11.2K | 0.01% | 840 |
|
|
2021
Q2 | $1.65M | Buy |
10,200
+1,300
| +15% | +$210K | 0.01% | 686 |
|
|
2021
Q1 | $1.08M | Hold |
8,900
| – | – | 0.01% | 800 |
|
|
2020
Q4 | $1.36M | Sell |
8,900
-2,400
| -21% | -$368K | 0.01% | 703 |
|
|
2020
Q3 | $945K | Buy |
11,300
+5,300
| +88% | +$443K | 0.01% | 745 |
|
|
2020
Q2 | $441K | Buy |
+6,000
| New | +$441K | ﹤0.01% | 1018 |
|